Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
Pancreatic ductal adenocarcinoma is characterized by its high morbidity, and curative drugs are still lacking. In addition to immunotherapy, other molecular targeted therapeutics, such as stroma depleting agents, have been evaluated, given the abundant desmoplastic stroma that is considered a protective shield for tumor cells. However, the unexpected poor outcome has raised the debate on whether desmoplasia promotes or restrains tumor cell spread. After reviewing these key points in this paper, an approach taking advantage of desmoplasia and immune cells to besiege the tumoral sites will be proposed. Based on the available literature, the feasibility and potential limitations of this strategy will be discussed.
['Delma|Mohamed Islam|MI|']
pancreatic ductal adenocarcinoma desmoplasia granuloma immune checkpoint inhibitors macrophages